Image

Global Anti Arrhythmic Drugs Market – Industry Trends and Forecast to 2029

Pharmaceutical

Image

Global Anti Arrhythmic Drugs Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • Oct 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Anti Arrhythmic Drugs Market – Industry Trends and Forecast to 2029

Market Size in USD Billion

CAGR :  % Diagram

Diagram Forecast Period 2021–2029
Diagram Market Size (Base Year) USD 1.04 Billion
Diagram Market Size (Forecast Year) USD 1.60 Billion
Diagram CAGR %

Major Markets Players

  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

Global Anti Arrhythmic Drugs Market, By Drug class (Beta Blockers, Calcium Chain Blockers, sodium channel blockers, potassium channel blockers), Drugs (Amiodarone, Flecainide, Ibutilide, Others), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.

Anti Arrhythmic Drugs

Anti Arrhythmic Drugs Market Analysis and Size

The global anti arrhythmic drugs market is expected to witness huge growth in the forecast period. On an average, the rate of maintaining sinus rhythm is nearly closer to 30% to 50% at one year for the other tested anti arrhythmic drugs. The COVID-19 pandemic has restated the importance of maintaining heart health as patients suffering from heart-related comorbidities have been found to be at major risk of contracting the coronavirus. These drugs must be taken regularly for one to three weeks before a response is witnessed and for numerous months before the full effect occurs.

Data Bridge Market Research analyses a growth rate in the global anti arrhythmic drugs market in the forecast period 2022-2029. The expected CAGR of global anti arrhythmic drugs market is tend to be around 5.50% in the mentioned forecast period. The market was valued at USD 1.04  billion in 2021, and it would grow upto USD 1.60 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

Anti-arrhythmic drugs are the type of therapeutics that belongs to the class of cardiovascular agents which are widely used in the management of patients suffering from cardiac arrhythmias. It exerts their action by controlling abnormal cardiac rhythm resulting from irregular electrical conductivity of the heart.  Most arrhythmia medications are taken by mouth during a long period of time for lasting treatment. Some are taken intravenously for patients who are unstable or are not suitable for oral medications.

Anti Arrhythmic Drugs Market Scope and Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2014 - 2019)

Quantitative Units

Revenue in USD Billion, Volumes in Units, Pricing in USD

Segments Covered

Drug class (Beta Blockers, Calcium Chain Blockers, sodium channel blockers, potassium channel blockers), Drugs (Amiodarone, Flecainide, Ibutilide, Others), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

F. Hoffmann-La Roche Ltd (Switzerland), Fresenius Kabi AG (Germany), Bayer AG (Germany), Sun Pharmaceutical Industries Ltd (India), Novartis AG (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd (Israel), Pfizer Inc (U.S.), Lupin (India), GSK Plc (U.K.), Glenmark Pharmaceuticals Inc (India), Amneal Pharmaceuticals (U.S.), Wockhardt (India)

Market Opportunities

  • Increasing Adoption of Arrhythmic Drugs in ICU
  • Increase in Elderly Population

Global Anti Arrhythmic Drugs Market Dynamics

Drivers

  • Increase in Cardiovascular Diseases

According to the WHO, around 60% - 85% of population have adopted a sedentary life. According to CDC, approximately 31 million adults aged over 50 years lives a sedentary life, and only 1 out of 4 U.S. adults meets the appropriate need of physical activity. As a result, arrhythmic drugs are used widely to prevent this. This boost the market growth.

  • Rising Demand for Oral Drugs

Oral drugs is expected to boost the market growth. The segment is expected to accelerate the global market as most products are available in capsule and tablet form and it is a very feasible route of administration.

Opportunities

  • Increasing Adoption of Arrhythmic Drugs in ICU

As per the reports of NCBI, atrial fibrillation is observed in around 30% of medical intensive care units(MICU) patients. Many serious issues were observed in critically ill patients. Thus, in this regard, arrhythmic drugs are of great help to treat these patients. Thus, it creates more opportunity for the market growth.

  • Increase in Elderly Population

The expansion of the atrial fibrillation market is prompted by rise in the frequency of atrial fibrillation in the elderly population, technical developments, and a preference for catheter ablation for cardiac arrhythmia therapy. Thus, it is helpful in driving the market growth.

 Restraints/Challenges

  • Lack of skilled professionals

The lack of qualified personnel who are unable to treat the patients with these drugs could curb the growth of the global anti arrhythmic drugs market over a forecast period.

  • Side Effects of arrhythmic drugs

There are various side-effects associated with the arrhythmic drugs that surely hamper the market growth. Effects such as dizziness, nausea, cardiovascular toxicity, gastrointestinal symptoms, immune-medicated reactions and many more are restricting the growth of the market.

This global anti arrhythmic drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global anti arrhythmic drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Anti Arrhythmic Drugs Market            

The COVID-19 pandemic has significantly impacted the global anti arrhythmic drugs market. Several reports stated that around 16.7% of the hospitalized patients and 44.4% of patients in intensive care units (ICUs) had cardiac arrhythmia. Another study by Perelman School of Medicine at the University of Pennsylvania in July 2020 showed that the onset of the COVID-19 infection was associated with an increasing incidence of cardiac arrhythmias in patients.

The infection, in many cases, has deteriorated the pre-existing conditions, causing higher mortality rates among patients with chronic heart diseases. The coronavirus has, thus, intensified the adoption of critical care anti- arrhythmic drugs worldwide.

Global Anti Arrhythmic Drugs Market Scope

The global anti arrhythmic drugs market is segmented on the basis of drugs, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug class

  • Beta Blockers
  • Calcium Chain Blockers,
  • Sodium channel blockers
  • Potassium channel blockers

Drugs

  • Amiodarone
  • Flecainide
  • Ibutilide
  • Others

Route of Administration

  • Oral
  • Parenteral

End User

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

Anti Arrhythmic Drugs Market Regional Analysis/Insights

The global anti arrhythmic drugs market is analysed and market size insights and trends are provided by drugs, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global anti arrhythmic drugs market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America has been witnessing a positive growth for global anti arrhythmic drugs market throughout the forecasted period due to the increase prevalence of cardiovascular complications and advanced healthcare facilities.

Asia-Pacific dominates the market due to the increase’s cases of cardiovascular diseases and rapidly aging population.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Anti Arrhythmic Drugs Market Share Analysis

The global anti arrhythmic drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global anti arrhythmic drugs market.

Key players operating in the global anti arrhythmic drugs market include:

  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Fresenius Kabi AG (Germany)
  • Bayer AG (Germany)
  • Sun Pharmaceutical Industries Ltd (India)
  • Novartis AG (Switzerland)
  • Mylan N.V. (U.S.)
  • Teva Pharmaceutical Industries Ltd (Israel)
  • Pfizer Inc (U.S.)
  • Lupin (India)
  • GSK Plc (U.K.)
  • Glenmark Pharmaceuticals Inc (India)
  • Amneal Pharmaceuticals (U.S.)
  • Wockhardt (India)


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

FREQUENTLY ASK QUESTIONS

The Anti Arrhythmic Drugs Market is projected to grow at a CAGR of 5.50% during the forecast period by 2029.
The future market value of the Anti Arrhythmic Drugs Market is expected to reach USD 1.60 billion by 2029.
The major players in the Anti Arrhythmic Drugs Market are F. Hoffmann-La Roche Ltd (Switzerland), Fresenius Kabi AG (Germany), Bayer AG (Germany), Sun Pharmaceutical Industries Ltd (India), Novartis AG (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd (Israel), etc.
The countries covered in the Anti Arrhythmic Drugs Market are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, etc.
Free Sample Report

CHOOSE LICENCE TYPE

  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials